Cetera Investment Advisers Buys 4,342 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Cetera Investment Advisers grew its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 723,840 shares of the biopharmaceutical company’s stock after acquiring an additional 4,342 shares during the quarter. Cetera Investment Advisers’ holdings in Ocular Therapeutix were worth $6,182,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Atlas Capital Advisors Inc. purchased a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $43,000. AlphaQuest LLC purchased a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $53,000. Tower Research Capital LLC TRC raised its stake in shares of Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 8,446 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $90,000. Finally, XTX Topco Ltd purchased a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $99,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Stock Down 5.3%

Shares of NASDAQ OCUL opened at $7.00 on Wednesday. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 52 week low of $4.79 and a 52 week high of $11.78. The firm’s fifty day moving average is $7.46 and its 200 day moving average is $8.23. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -5.30 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. On average, equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OCUL has been the topic of several research reports. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price target on the stock. William Blair initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an “outperform” rating on the stock. Needham & Company LLC decreased their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.25.

Insider Buying and Selling at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction on Thursday, May 8th. The shares were acquired at an average cost of $6.96 per share, with a total value of $69,600.00. Following the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.